First National Trust Co. Acquires 1,195 Shares of AbbVie Inc (ABBV)

First National Trust Co. boosted its holdings in AbbVie Inc (NYSE:ABBV) by 0.9% during the third quarter, HoldingsChannel.com reports. The firm owned 132,055 shares of the company’s stock after acquiring an additional 1,195 shares during the quarter. AbbVie comprises about 1.4% of First National Trust Co.’s portfolio, making the stock its 15th largest holding. First National Trust Co.’s holdings in AbbVie were worth $11,734,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Iberiabank Corp lifted its stake in shares of AbbVie by 1.2% in the second quarter. Iberiabank Corp now owns 81,633 shares of the company’s stock worth $5,919,000 after buying an additional 934 shares in the last quarter. Lawson Kroeker Investment Management Inc. NE lifted its stake in shares of AbbVie by 2.4% in the second quarter. Lawson Kroeker Investment Management Inc. NE now owns 4,546 shares of the company’s stock worth $330,000 after buying an additional 106 shares in the last quarter. Waverton Investment Management Ltd lifted its stake in shares of AbbVie by 2.8% in the second quarter. Waverton Investment Management Ltd now owns 10,455 shares of the company’s stock worth $758,000 after buying an additional 286 shares in the last quarter. Private Trust Co. NA lifted its position in AbbVie by 6.4% during the second quarter. Private Trust Co. NA now owns 86,540 shares of the company’s stock valued at $6,274,000 after purchasing an additional 5,219 shares during the period. Finally, Capital Investment Advisors LLC lifted its position in AbbVie by 3.5% during the second quarter. Capital Investment Advisors LLC now owns 25,330 shares of the company’s stock valued at $1,837,000 after purchasing an additional 868 shares during the period. Institutional investors and hedge funds own 69.22% of the company’s stock.

Shares of AbbVie Inc (NYSE ABBV) opened at $104.64 on Monday. AbbVie Inc has a twelve month low of $59.27 and a twelve month high of $104.87. The company has a market cap of $167,050.42, a P/E ratio of 25.46, a price-to-earnings-growth ratio of 1.22 and a beta of 1.52. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. During the same period in the prior year, the company earned $1.21 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. equities research analysts predict that AbbVie Inc will post 5.56 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a dividend of $0.71 per share. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date of this dividend is Thursday, January 11th. AbbVie’s dividend payout ratio is currently 69.10%.

A number of research analysts recently weighed in on ABBV shares. UBS Group downgraded shares of AbbVie from a “buy” rating to a “neutral” rating and increased their price objective for the company from $79.00 to $92.00 in a research report on Monday, September 25th. Jefferies Group restated a “buy” rating and set a $107.00 price objective on shares of AbbVie in a research report on Thursday, September 28th. Deutsche Bank increased their price objective on shares of AbbVie to $88.00 and gave the company a “hold” rating in a research report on Thursday, September 28th. Morgan Stanley increased their price objective on shares of AbbVie from $70.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, September 29th. Finally, Argus increased their price objective on shares of AbbVie from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, September 29th. Six equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $101.38.

In other news, insider Henry O. Gosebruch sold 18,300 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $90.55, for a total value of $1,657,065.00. Following the completion of the sale, the insider now directly owns 81,287 shares of the company’s stock, valued at $7,360,537.85. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Timothy J. Richmond sold 87,040 shares of the stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the sale, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 494,676 shares of company stock valued at $47,237,938. 0.23% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2018/01/22/first-national-trust-co-acquires-1195-shares-of-abbvie-inc-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit